

CSF and PET β -amyloid in AD Trials

Convergence and Divergence

Proposed Staging of Preclinical AD


Definitions for the preclinical stages of AD were recently outlined by the US National Institute on Aging:¹


- Stage 1: Asymptomatic cerebral amyloidosis
- Stage 2: Amyloidosis + evidence of neurodegeneration or neuronal injury
- Stage 3: Amyloidosis + neurodegeneration + evidence of subtle cognitive decline

Two additional categories have since been proposed:⁵


- Stage 0: Older individuals with no biomarker evidence of AD pathology
- Suspected Non-Alzheimer Pathology (SNAP): Individuals showing biomarkers of neurodegeneration without positive markers of amyloid accumulation

Proposed model for biomarker measurement sequence







Fagan Ann Neurol 2006



Grimmer Biol Psych 2009



Landau Ann Neurol 2013

CSF vs PET amyloid in DIAN

